Analysts have been eager to weigh in on the Healthcare sector with new ratings on Galapagos (GLPG), DaVita (DVA) and Pfizer (PFE).
Galapagos (GLPG)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos, with a price target of $139.00. The company’s shares closed last Wednesday at $137.05, close to its 52-week low of $112.00.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 9.8% and a 51.4% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $163.67, a 19.1% upside from current levels. In a report issued on September 11, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
DaVita (DVA)
In a report issued on September 15, Frank Morgan from RBC Capital maintained a Hold rating on DaVita, with a price target of $91.00. The company’s shares closed last Wednesday at $91.84, close to its 52-week high of $92.16.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 12.4% and a 63.6% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care, Acadia Healthcare, and Community Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for DaVita with a $97.60 average price target, implying a 7.3% upside from current levels. In a report issued on September 15, Raymond James also maintained a Hold rating on the stock.
Pfizer (PFE)
In a report issued on September 15, Randall Stanicky from RBC Capital maintained a Buy rating on Pfizer, with a price target of $43.00. The company’s shares closed last Wednesday at $36.78.
According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -7.1% and a 33.5% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $43.13 average price target, representing a 15.7% upside. In a report issued on September 8, Mizuho Securities also assigned a Buy rating to the stock with a $43.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PFE:
